Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary?
Tiliakos, A.N.; Tiliakos, N.A.
Journal of Rheumatology 30(12): 2727
2003
ISSN/ISBN: 0315-162X PMID: 14719226 Document Number: 561202
Document emailed within 1 workday
Related Documents
Pratsidou-Gertsi, P.; Trachana, M.; Pardalos, G.; Kanakoudi-Tsakalidou, F. 2010: A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission Clinical and Experimental Rheumatology 28(6): 919-922Scheinfeld, N. 2004: The medical uses and side effects of etanercept with a focus on cutaneous disease Journal of Drugs in Dermatology: Jdd 3(6): 653-659
Kalb, R.E.; Blauvelt, A.; Sofen, H.L.; Chevrier, M.; Amato, D.; Calabro, S.; Wang, J.; Schenkel, B.; Gottlieb, A.B. 2013: Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial Journal of Drugs in Dermatology: Jdd 12(8): 874-880
Forouzandeh, M.; Vazquez, T.; Nouri, K.; Forouzandeh, B. 2019: The Paradoxical Induction of Crohn's Disease Following Treatment of Psoriatic Arthritis with Etanercept Journal of Drugs in Dermatology: Jdd 18(8): 832-834
Shetty, A.; Marcum, C.B.; Glass, L.F.; Carter, J.D. 2009: Successful treatment of pemphigus vulgaris with etanercept in four patients Journal of Drugs in Dermatology: Jdd 8(10): 940-943
Melikoglu, M.; Fresko, I.; Mat, C.; Ozyazgan, Y.; Gogus, F.; Yurdakul, S.; Hamuryudan, V.; Yazici, H. 2005: Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study Journal of Rheumatology 32(1): 98-105
Abuchar, A.; Vitiello, M.; Ricotti, C.; Grant, A.; Dehesa, L.; Kerdel, F. 2012: Open label study to evaluate the efficacy of re-treatment with etanercept in patients with psoriasis Journal of Drugs in Dermatology: Jdd 11(8): 950-954
Briot, K.; Roux, C.; Gossec, L.; Charni, N.; Kolta, S.; Dougados, M.; Garnero, P. 2008: Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy Journal of Rheumatology 35(2): 310-314
De Vlam, K.; Bruhwyler, J.; Boone, C. 2016: Maintenance of remission and monotherapy status over 66 months in patients with psoriatic arthritis receiving etanercept Clinical and Experimental Rheumatology 34(6): 1094-1097
Gottlieb, A.B.; Gordon, K.; Giannini, E.H.; Mease, P.; Li, J.; Chon, Y.; Maddox, J.; Weng, H.H.; Wajdula, J.; Lin, S.-L.; Baumgartner, S.W. 2011: Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications Journal of Drugs in Dermatology: Jdd 10(3): 289-300
Maksymowych, W.P.; Poole, A.Robin.; Hiebert, L.; Webb, A.; Ionescu, M.; Lobanok, T.; King, L.; Davis, J.C. 2005: Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis Journal of Rheumatology 32(10): 1911-1917
Kimball, A.B.; Jackson, J.M.; Sobell, J.M.; Boh, E.E.; Grekin, S.; Pharmd, E.B.Y.; Woolley, J.M.; Xia, H.A.; Chiou, C.-F.; Stevens, S.R. 2007: Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial Journal of Drugs in Dermatology: Jdd 6(3): 299-306
Yang, M.; Galebach, P.J.; Signorovitch, J.E.; Garg, V. 2017: Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world Clinical and Experimental Rheumatology 35(5): 791-798
Huang, Z.; Cao, J.; Li, T.; Zheng, B.; Wang, M.; Zheng, R. 2011: Efficacy and safety of ultrasound-guided local injections of etanercept into entheses of ankylosing spondylitis patients with refractory Achilles enthesitis Clinical and Experimental Rheumatology 29(4): 642-649
Potenza, C.; Raimondi, G.; Pampena, R.; Bernardini, N.; La Viola, G.; Tolino, E.; Zuber, S.; Scordamaglia, B.; Skroza, N. 2016: Cardiovascular Risk Evaluation through Heart Rate Variability (HRV) Analysis in Patients with Psoriasis before and after 12 Weeks of Etanercept Therapy: a Preliminary Prospective Study Acta Dermatovenerologica Croatica: Adc 24(3): 181-186
Detert, J.; Dziurla, R.é; Hoff, P.; Gaber, T.; Klaus, P.; Bastian, H.; Braun, T.; Schellmann, S.; Penzel, T.; Fietze, I.; Loeschmann, P.-A.; Jaehnig, P.; Straub, R.H.; Burmester, G.R.; Buttgereit, F. 2016: Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis Clinical and Experimental Rheumatology 34(5): 848-856
Huang, F.; Zhang, J.; Zheng, Y.; Xu, J.-h.; Li, X.-f.; Wu, H.-x.; Chen, Z.-w.; Zhao, Z.; Zhang, Y.-m. 2011: A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis Zhonghua Nei Ke Za Zhi 50(12): 1043-1047
Adams, D.R.; Zaenglein, A.L.; Hershey, M.S. 2004: Etanercept and warts Journal of Drugs in Dermatology: Jdd 3(6): 601
Morović-Vergles, J.; Martinović-Kaliterna, D. 2007: Etanercept (Enbrel)--our experiences Reumatizam 54(2): 69-70
Kircik, L.H. 2011: Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial Journal of Drugs in Dermatology: Jdd 10(8): 878-882